CNS Pharmaceuticals Inc. CNSP Archives - Page 22 of 22

ThursdayOct 01, 2020 10:38 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves Critical Milestone for Production of Lead Drug Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its GMP manufacturer partner NCK A/S, received a Certificate of Analysis (“CoA”) for its Active Pharma Ingredient (“API”), clearing it for use in the production of Berubicin. CNS Pharmaceuticals previously announced entry into a contract with NCK A/S, a GMP manufacturer of complex drugs and the previous producer of Berubicin for Reata Pharmaceuticals, for the large-scale production of Berubicin, CNSP’s lead drug candidate for the treatment of glioma brain tumors. "We…

TuesdaySep 29, 2020 12:36 pm

CNS Pharmaceuticals, Inc. (CNSP) Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.

Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020 CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025 CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has expanded its Scientific Advisory Board by welcoming new member Dr. Patrick Wen, M.D., a leading neurology and neuro-oncology expert (https://ibn.fm/VJ6e9). Dr. Wen joins current Board members,…

FridaySep 25, 2020 1:14 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, a novel DNA binding agent, was 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Industry reports estimate that the global brain…

ThursdaySep 24, 2020 11:04 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partners with Leading Medical Imaging Group for Upcoming Berubicin Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has announced that it will partner with Image Analysis Group (“IAG”) for planned Berubicin clinical trials. IAG, a leading medical imaging group, and CNS will work together to provide critical imaging services and imaging data analysis for the trials. IAG has an extensive background of partnering with oncology companies to deliver centralized readings and analysis of patient responses in real time. IAG’s expertise will allow CNS to review efficacy assessments and explore the advanced-treatment manifestations. Because…

WednesdaySep 23, 2020 12:53 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Mines Investment-building Opportunity for Brain Tumor-Targeting Drug Candidate at Annual Conference

CNS Pharmaceuticals is a clinical-stage biotechnology company developing therapies to combat aggressive cancers of the brain and central nervous system The company will be applying for approval to launch Phase II trials in the first quarter of 2021 for its leading drug candidate, Berubicin, which targets glioblastoma multiforme (“GBM”) brain cancer CNS Pharmaceuticals CEO addressed the company’s achievements and its vision for Berubicin development during the recent 22nd annual Global Investment Conference sponsored by H.C. Wainwright & Co. C. Wainwright is a full-service investment bank focused on capital markets and equity research in market sectors that hinge on industries encompassing…

TuesdaySep 22, 2020 4:59 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), Sub-Licensee Partner Advancing Lead Drug Candidate in First-Ever Phase 1 and Phase 2 Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing its leading drug candidate, Berubicin, to move forward with clinical trials in Poland. This move comes after sub-licensee WPD Pharmaceuticals Inc. has identified a contract research organization — Worldwide Clinical Trials — to coordinate and supervise Phase 1 and Phase 2 trials in the European country (http://ibn.fm/iFYph). A recent article discussing this reads, “Berubicin is proposed for the treatment of glioblastoma multiforme (‘GBM’), an aggressive and incurable form of brain cancer. Berubicin also…

ThursdaySep 17, 2020 11:28 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Sub-Licensee Partner Announces CRO for Phase 1 and Phase 2 Berubicin Trials in Poland

Poland trials will include the first ever Phase 1 trial for pediatric patients suffering from glioblastoma multiforme CNS Pharmaceuticals has made significant strides in its Berubicin manufacturing process due to its dual-track approach and expects to begin production of its drug candidate at Pharmaceuticals International during the third quarter of 2020 The Company’s CFO recently acquired 142,000 shares of common stock in the open market, a move indicative of his confidence in the success of Berubicin clinical trials and its positive impact on the global brain tumor therapeutics market CNS Pharmaceuticals (NASDAQ: CNSP) is moving forward with clinical trials of…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP